Manufacturers Life Insurance Company, The Geron Corp Transaction History

Manufacturers Life Insurance Company, The

$108 Billion
Q3 2024

A detailed history of Manufacturers Life Insurance Company, The transactions in Geron Corp stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 695,535 shares of GERN stock, worth $2.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

695,535

Previous 915,949 24.06%

Holding current value

$2.36 Million

Previous $3.88 Million 18.7%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$4.17 - $4.99 $919,126 - $1.1 Million	-220,414 Reduced 24.06%	695,535 $3.16 Million
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $1.71 Million - $2.82 Million	553,081 Added 152.42%	915,949 $3.88 Million
Q1 2024 May 14, 2024	BUY	$1.75 - $3.44 $178,571 - $351,021	102,041 Added 39.12%	362,868 $1.2 Million
Q4 2023 Feb 13, 2024	BUY	$1.74 - $2.31 $2,263 - $3,005	1,301 Added 0.5%	260,827 $550,000
Q3 2023 Nov 15, 2023	BUY	$2.11 - $3.28 $127,104 - $197,583	60,239 Added 30.23%	259,526 $550,000
Q2 2023 Aug 11, 2023	BUY	$1.97 - $3.69 $117,412 - $219,924	59,600 Added 42.67%	199,287 $639,000
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $16,124 - $25,619	7,535 Added 5.39%	147,222 $319,000
Q4 2022 Aug 11, 2023	SELL	$2.03 - $2.42 $5,740 - $6,843	-2,828 Reduced 1.98%	139,687 $338,000
Q4 2022 Feb 13, 2023	SELL	$2.03 - $2.42 $5,740 - $6,843	-2,828 Reduced 1.98%	139,687 $338,000
Q3 2022 Aug 11, 2023	SELL	$1.67 - $2.94 $8,057 - $14,185	-4,825 Reduced 3.27%	142,515 $333,000
Q3 2022 Nov 03, 2022	SELL	$1.67 - $2.94 $8,057 - $14,185	-4,825 Reduced 3.27%	142,515 $333,000
Q2 2022 Aug 11, 2023	BUY	$1.19 - $1.65 $15,514 - $21,511	13,037 Added 9.71%	147,340 $228,000
Q2 2022 Aug 15, 2022	BUY	$1.19 - $1.65 $15,514 - $21,511	13,037 Added 9.71%	147,340 $228,000
Q1 2022 Aug 11, 2023	SELL	$0.99 - $1.6 $12,789 - $20,670	-12,919 Reduced 8.78%	134,303 $182,000
Q1 2022 May 20, 2022	SELL	$0.99 - $1.6 $38,062 - $61,515	-38,447 Reduced 22.26%	134,303 $183,000
Q4 2021 Feb 16, 2022	SELL	$1.22 - $1.72 $7,629 - $10,756	-6,254 Reduced 3.49%	172,750 $211,000
Q3 2021 Nov 12, 2021	SELL	$1.2 - $1.5 $11,679 - $14,599	-9,733 Reduced 5.16%	179,004 $245,000
Q2 2021 Aug 12, 2021	BUY	$1.25 - $1.83 $18,465 - $27,032	14,772 Added 8.49%	188,737 $266,000
Q1 2021 May 03, 2021	SELL	$1.52 - $2.1 $5,668 - $7,830	-3,729 Reduced 2.1%	173,965 $275,000
Q4 2020 Feb 12, 2021	BUY	$1.55 - $2.05 $25,334 - $33,507	16,345 Added 10.13%	177,694 $283,000
Q3 2020 Nov 09, 2020	BUY	$1.59 - $2.19 $72,887 - $100,391	45,841 Added 39.69%	161,349 $281,000
Q2 2020 Aug 10, 2020	SELL	$1.05 - $2.18 $8,277 - $17,184	-7,883 Reduced 6.39%	115,508 $243,000
Q1 2020 May 15, 2020	BUY	$0.89 - $1.49 $14,452 - $24,196	16,239 Added 15.16%	123,391 $147,000
Q4 2019 Feb 14, 2020	SELL	$1.27 - $1.54 $11,454 - $13,889	-9,019 Reduced 7.76%	107,152 $146,000
Q2 2019 Aug 14, 2019	SELL	$1.37 - $2.02 $4,457 - $6,573	-3,254 Reduced 2.72%	116,171 $164,000
Q1 2019 May 13, 2019	SELL	$1.01 - $1.83 $1,495 - $2,710	-1,481 Reduced 1.22%	119,425 $198,000
Q4 2018 Feb 14, 2019	BUY	$0.98 - $1.85 $10,065 - $19,001	10,271 Added 9.28%	120,906 $121,000
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $19,372 - $70,224	-11,007 Reduced 9.05%	110,635 $195,000
Q2 2018 Aug 14, 2018	BUY	$3.29 - $4.82 $25,678 - $37,620	7,805 Added 6.86%	121,642 $418,000
Q1 2018 May 15, 2018	SELL	$1.81 - $5.98 $7,739 - $25,570	-4,276 Reduced 3.62%	113,837 $484,000
Q4 2017 Feb 08, 2018	SELL	$1.8 - $2.32 $2,658 - $3,426	-1,477 Reduced 1.24%	118,113 $213,000
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $237,984 - $316,913	119,590	119,590 $260,000

Others Institutions Holding GERN

# of Institutions

274

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.28B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.

Account

Manufacturers Life Insurance Company, The Geron Corp Transaction History